CAS: 73-31-4; N-(2-(5-Methoxy-1H-Indol-3-yl)Ethyl)Acetamide

相似化合物

1210-83-9 28026-16-6 229018-17-1

上下游产品

CAS号608-07-1 5-甲氧基色胺 | CAS号108-24-7 乙酸酐 | CAS号1210-83-9 N-乙酰-5-羟基色胺 | CAS号77-78-1 硫酸二甲酯 | CAS号692-33-1 Acetamide,N-2-p... | CAS号201230-82-2 carbon monoxide | CAS号19501-58-7 4-甲氧基苯肼盐酸盐 | CAS号28772-49-8 2-(2,4-dinitrop... | CAS号2735-73-1 1,3-Diacetyl-1,... | CAS号112081-40-0 N-[2-(5-methoxy... | CAS号50-67-9 5-羟基色胺 | CAS号362-43-6 2',3'-异丙基脲 | CAS号68798-00-5 5-[3-[2-(acetyl... | CAS号608-07-1 5-甲氧基色胺 | CAS号3589-73-9 6-甲氧基哈马兰 | CAS号304854-99-7 N-[2-(5-methoxy... | CAS号2537-74-8 6-methoxy-1-met... | CAS号188397-05-9 6-Acetyl-3-[2-(... | CAS号1210-83-9 N-乙酰-5-羟基色胺

N-(2-{5-甲氧基-1-[(4-甲基苯基)磺酰基]-1H-吲哚-3-基}乙基)乙酰胺置于n,N-二甲基丙烯基脲,三(2-氨基乙基)胺,Cadmium Sulphide体系中,用 甲苯 作为反应溶剂,化学反应 24.0H,以68%的收率获得产物褪黑素
参考文献:Cds 量子点作为有机化学的有效光还原剂,通过俄歇工艺实现
标题:Cds 量子点作为有机化学的有效光还原剂,通过俄歇工艺实现
摘要:强还原剂(相对于饱和甘汞电极(sce)<−2.0 V)可实现多种有用的有机化学,但受到各种限制.这些反应通常采用化学计量的金属还原剂,例如碱金属和smi 2 .然而,包括费用,易用性,安全性和废物产生在内的考虑因素限制了这些方法的实用性.最近利用多光子或电子引发的光氧化还原催化能量的方法已经获得了相当于 Li 0的还原电位并展示了这如何能够通过芳基自由基选择性转化芳基氯.然而,在某些情况下,催化中间体的稳定性较低可能会限制营业额.在此,我们报告了 Cds 纳米晶体量子点(qd)作为强光还原剂的能力,并提供了证据表明,通过中间还原猝灭的 Cds Qd 的两次连续光激发产生高度还原电子.机械实验表明,俄歇复合(一种已知发生在光激发阴离子量子点中的光物理现象)会产生瞬态热激发电子,从而实现观测到的还原.使用蓝色发光二极管 (Led) 和牺牲胺还原剂,芳基氯和还原电位高达-3 的磷酸酯.4 V Vs
DOI:10.1021/jacs.2C03235

专利信息

专利号:US-7759520-B2
优先权日:1996-11-27
标 题 :Synthesis of selective androgen receptor modulators
发明人：DALTON JAMES T; MILLER DUANE D; YIN DONGHUA; HE YALI
权利人:UNIV TENNESSEE RES FOUNDATION
摘要:The present invention relates to a synthetic process for the preparation of a novel class of androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds which are selective androgen receptor modulators (SARM) which are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen relacement and/or other clinical therpauetic and/or diagnostic areas. The process of the present invention is suitable for large-scale preparation, since all of the steps give rise to highly pure compounds, thus avoiding complicated purification procedures which ultimately lower the yield. Thus the present invention provides methods for the synthesis of non-steroidal agonist compounds, that can be used for industrial large-scale synthesis, and that provide highly pure products in high yield.

专利号:US-2012177593-A1
优先权日:2009-07-20
标 题 :Synthesis of dendrimer conjugates
发明人：BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH
权利人:BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH; UNIV MICHIGAN
摘要:The present invention relates to novel methods of synthesis of therapeutic and diagnostic dendrimers. In particular, the present invention is directed to novel dendrimer conjugates, novel methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer, inflammatory disease) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer conjugates of the present invention may further comprise at least two different components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy. Furthermore, the novel synthesis methods of certain embodiments of the present invention provide significant advantages with regard to total reaction time and simplicity.

专利号:US-6995284-B2
优先权日:2000-08-24
标题 :Synthesis of selective androgen receptor modulators
发明人：DALTON JAMES T; MILLER DUANE D; HE YALI; YIN DONGHUA
权利人:UNIV TENNESSEE RES FOUNDATION
摘要:The present invention relates to a synthetic process for the preparation of a novel class of androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds which are selective androgen receptor modulators (SARM) which are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen relacement and/or other clinical therpauetic and/or diagnostic areas. The process of the present invention is suitable for large-scale preparation, since all of the steps give rise to highly pure compounds, thus avoiding complicated purification procedures which ultimately lower the yield. Thus the present invention provides methods for the synthesis of non-steroidal agonist compounds, that can be used for industrial large-scale synthesis, and that provide highly pure products in high yield.

专利号:US-2011184058-A1
优先权日:2008-07-14
标 题:Synthesis of 6,7-dihydro-1h-indeno[5, 4-b] furan-8(2h)-one as intermediate in the preparation of remelteon
发明人：CLUZEAU JEROME
权利人:LEK PHARMACEUTICALS
摘要:The present invention describes the preparation of 6,7-dihydro-1H-indeno[5,4-b]furan-8(2H)-one, a key intermediate in preparation of ramelteon. The present invention also describes further preceding intermediate compounds useful for the synthesis of 6,7-dihydro-1H-indeno[5,4-b]furan-8(2H)-one.

专利号:US-7662401-B2
优先权日:2002-04-08
标 题 :Administration of extracts of nonfruiting nonphotosynthetic filamentous bacteria for increasing the endogenous synthesis of superoxide dismutase
发明人：MAHE YANN; MEYBECK ALAIN
权利人:OREAL
摘要:The present invention relates to the cosmetic or pharmaceutical use of an extract of a nonfruiting nonphotosynthetic filamentous bacterium in a composition containing a cosmetically or pharmaceutically acceptable medium, as an agent increasing the endogenous synthesis of superoxide dismutase, in particular for preventing and/or limiting the formation of free radicals and/or removing the free radicals present in cells; in addition, the invention relates to a composition comprising at least one extract of Vitreoscilla filiformis and lycopene.

专利号:WO-2023148680-A1
优先权日:2022-02-04
标 题 :Methods for large scale synthesis of radionuclide complexes
发明人：BARBATO DONATO; BO MICHELE; ROSSETTO MATTIA; TEDESCO MATTIA; VALERIO FEDERICO
权利人:ADVANCED ACCELERATOR APPLICATIONS
摘要:The present disclosure relates to methods of large scale synthesis of radionuclide complex solutions having a high activity for diagnostic and/or therapeutic purposes, their use in the commercial production of radioactive drug substances, and to respective solutions as well as containers comprising said solutions.